Portal de Periódicos da CAPES

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

2017; Elsevier BV; Volume: 129; Issue: 10 Linguagem: Inglês

10.1182/blood-2016-09-738385

1528-0020

Reid W. Merryman, Haesook T. Kim, Pier Luigi Zinzani, Carmelo Carlo‐Stella, Stephen M. Ansell, M.-A. Perales, Abraham Avigdor, Ahmad Halwani, Roch Houot, Tony Marchand, Nathalie Dhédin, W. Lescaut, Anne Thiebaut‐Bertrand, Sylvie François, Aspasia Stamatoullas‐Bastard, Pierre-Simon Rohrlich, Hélène Labussière Wallet, Luca Castagna, Armando Santoro, Veronika Bachanová, Scott C. Bresler, Amitabh Srivastava, Harim Kim, Emily Pesek, Marie J Chammas, Carol Reynolds, Vincent T. Ho, Joseph H. Antin, Jerome Ritz, Robert J. Soiffer, Philippe Armand,

Immune Cell Function and Interaction

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.